Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

346 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy.
Tahata Y, Hiramatsu N, Oze T, Urabe A, Morishita N, Yamada R, Yakushijin T, Hosui A, Oshita M, Kaneko A, Hagiwara H, Mita E, Ito T, Yamada Y, Inada M, Katayama K, Tamura S, Imai Y, Hikita H, Sakamori R, Yoshida Y, Tatsumi T, Hayashi N, Takehara T. Tahata Y, et al. Among authors: urabe a. J Med Virol. 2016 Oct;88(10):1776-84. doi: 10.1002/jmv.24528. Epub 2016 Mar 29. J Med Virol. 2016. PMID: 26991414
Ultra-deep sequencing analysis of resistance-associated variants during retreatment with simeprevir-based triple therapy after failure of telaprevir-based triple therapy in patients with genotype 1 hepatitis C virus infection.
Morishita N, Hiramatsu N, Oze T, Urabe A, Tahata Y, Yamada R, Yakushijin T, Hosui A, Iio S, Yamada A, Hagiwara H, Mita E, Yamada Y, Ito T, Inada M, Katayama K, Yabuuchi I, Imai Y, Hikita H, Sakamori R, Yoshida Y, Tatsumi T, Hayashi N, Takehara T. Morishita N, et al. Among authors: urabe a. Hepatol Res. 2017 Jul;47(8):773-782. doi: 10.1111/hepr.12817. Epub 2016 Oct 26. Hepatol Res. 2017. PMID: 27593967
Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection.
Morishita N, Sakamori R, Yamada T, Kai Y, Tahata Y, Urabe A, Yamada R, Kodama T, Hikita H, Doi Y, Tamura S, Hagiwara H, Imai Y, Iio S, Tatsumi T, Takehara T. Morishita N, et al. Among authors: urabe a. PLoS One. 2020 Jun 16;15(6):e0234811. doi: 10.1371/journal.pone.0234811. eCollection 2020. PLoS One. 2020. PMID: 32544182 Free PMC article.
Lower Serum Sodium Levels Are Associated with the Therapeutic Effect of Sorafenib on Hepatocellular Carcinoma.
Kegasawa T, Sakamori R, Maesaka K, Yamada R, Tahata Y, Urabe A, Kodama T, Hikita H, Imanaka K, Ohkawa K, Hiramatsu N, Oshita M, Yamada Y, Inada M, Yakushijin T, Imai Y, Tatsumi T, Takehara T. Kegasawa T, et al. Among authors: urabe a. Dig Dis Sci. 2021 May;66(5):1720-1729. doi: 10.1007/s10620-020-06380-6. Epub 2020 Jun 17. Dig Dis Sci. 2021. PMID: 32556820
Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all-oral direct-acting antivirals: Analysis of a Japanese prospective cohort.
Doi A, Sakamori R, Tahata Y, Urabe A, Morishita N, Yamada R, Furuta K, Kodama T, Hikita H, Yakushijin T, Ohkawa K, Kaneko A, Imai Y, Tatsumi T, Takehara T. Doi A, et al. Among authors: urabe a. Hepatol Res. 2017 Dec;47(13):1438-1444. doi: 10.1111/hepr.12919. Epub 2017 Aug 1. Hepatol Res. 2017. PMID: 28585404
Liver Fibrosis Is Associated With Corrected QT Prolongation During Ledipasvir/Sofosbuvir Treatment for Patients With Chronic Hepatitis C.
Tahata Y, Sakamori R, Urabe A, Morishita N, Yamada R, Yakushijin T, Hiramatsu N, Doi Y, Kaneko A, Hagiwara H, Yamada Y, Hijioka T, Inada M, Tamura S, Imai Y, Furuta K, Kodama T, Hikita H, Tatsumi T, Takehara T. Tahata Y, et al. Among authors: urabe a. Hepatol Commun. 2018 Aug 6;2(8):884-892. doi: 10.1002/hep4.1206. eCollection 2018 Aug. Hepatol Commun. 2018. PMID: 30094400 Free PMC article.
Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response.
Yamada R, Hiramatsu N, Oze T, Urabe A, Tahata Y, Morishita N, Kodama T, Hikita H, Sakamori R, Yakushijin T, Yamada A, Hagiwara H, Mita E, Oshita M, Itoh T, Fukui H, Inui Y, Hijioka T, Inada M, Katayama K, Tamura S, Inoue A, Imai Y, Tatsumi T, Hamasaki T, Hayashi N, Takehara T. Yamada R, et al. Among authors: urabe a. Hepatol Res. 2019 May;49(5):570-578. doi: 10.1111/hepr.13310. Epub 2019 Feb 6. Hepatol Res. 2019. PMID: 30623521
346 results